Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy...

Annals of Oncology 2016 / 10 Vol. 27; Iss. suppl_6

Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial

Kasper, S., Meiler, J., Knipp, H., Höhler, T., Reimer, P., Steinmetz, H.T., Berger, W., Linden, G., Ting, S., Markus, P., Paul, A., Dechêne, A., Schumacher, B., Kostbade, K., Worm, K., Schmid, K.W., H
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw370.56
Date:
October, 2016
File:
PDF, 41 KB
english, 2016
Conversion to is in progress
Conversion to is failed